CME; patritumab deruxtecan; HER3-DXd; HERTHENA-Lung01; ILD

Overview
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Pasi A. Jänne, MD, PhD
Senior Vice President for Translational Medicine
David M. Livingston, MD, Chair
Lowe Center for Thoracic Oncology
Dana Farber Cancer Institute
Director, Belfer Center for Applied Cancer Science
Professor of Medicine, Harvard Medical School
Boston, MA
Dr. Jänne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: AbbVie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Blueprint Medicines, Boehringer Ingelheim, Chugai Pharmaceuticals, Daiichi Sankyo, Duality Biologics, Eisai, Eli Lilly, Frontier, HongyunBiotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta, Voronoi
Stock Ownership: Gatekeeper Pharmaceuticals Research Funding: AstraZenenca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Puma, Revolution Medicines, Takeda Oncology
Royalties: LabCorp, from post-marketing royalties Dana-Farber Cancer Institute owned intellectual property on EGFR mutations licensed to Lab Corp
Helena A. Yu, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY
Dr. Yu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: AstraZeneca, Daiichi, Cullinan, Taiho, Systimmune, Pfizer, Novartis, ERASCA, Janssen
Consulting fees: AstraZeneca, Janssen, Daiichi, Taiho, Amgen, Abbvie
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Bing-E Xu has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate the biology of HER3 overexpression and the rationale for targeting HER3 in the treatment of EGFR-resistant non-small cell lung cancer (NSCLC)
- Increase confidence in the application of scientific evidence to create treatment strategies for patients with EGFR-resistant NSCLC progression after EFGR-TKI and platinum chemotherapy
- Develop evidence-based clinical strategies to implement novel antibody-drug conjugates (ADCs) in patients with advanced EGFR-mutated NSCLC previously treated with EGFR-TKIs and platinum-based chemotherapy
- Develop an integrated team-based approach for monitoring and managing treatment-related adverse events associated with HER3-directed ADCs
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with metastatic NSCLC.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 12/17/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/0.075 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-078-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)

It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/17/2024
Expiration Date: 12/17/2025